Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
News
FDA approves new drug for CLL/SLL and follicular lymphoma
Duvelisib (Copiktra) has full approval to treat CLL/SLL and accelerated approval to treat FL.
News
NICE looks likely to reject use of Kymriah for DLBCL
The U.K. agency issued draft guidance recommending against use of tisagenlecleucel (Kymriah) a month after issuing similar guidance about...
News
FDA grants OBI-3424 orphan designation for ALL
OBI-3424, an AKR1C3 prodrug, has previously demonstrated preclinical efficacy against ALL.
News
Researchers propose new acute leukemia subtypes
The researchers found genetic similarities between MPAL and other acute leukemias that could help refine treatment options.
News
ASCO addresses financial barriers to cancer clinical trials
ASCO outlines steps for payers and researchers to take to improve patient participation in cancer clinical trials.
News
Children with BCP-ALL show inflammatory marker differences at birth
Patients who develop B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in childhood may have dysregulated immune function at birth,...
News
Early CAR T data on P-BCMA-101 in refractory myeloma
P-BCMA-101 has demonstrated efficacy in a phase 1 trial of relapsed/refractory multiple myeloma.
Article
STORM trial shows response in penta-refractory myeloma
Selinexor and low-dose dexamethasone produced a “clinically meaningful benefit” in the phase 2 trial.
News
Von Willebrand disease product approved in Europe
Vonicog alfa (Veyvondi) is approved to treat or prevent bleeding in certain adults with von Willebrand disease.
News
FDA approves new hairy cell leukemia drug
Moxetumomab pasudotox-tdfk (Lumoxiti) is approved to treat adults with relapsed or refractory hairy cell leukemia.
News
Cell population appears to drive relapse in AML
“Leukemic-regenerating cells,” which are distinct from therapy-naive leukemic stem cells, may be responsible for relapse in acute myeloid leukemia...
News
Venetoclax label now includes MRD data
The MURANO trial showed high rates of minimal residual disease negativity in patients treated with the venetoclax combination.
News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).
News
England green-lights coverage of one CAR T-cell therapy
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.